Dr. George D. Demetri, M.D. is the Founder and Editor of Sarcoma.net. Dr. Demetri serves as a Scientific and Clinical Advisor at G1 Therapeutics, Inc. He serves as a Scientific Advisor of vTv Therapeutics LLC (alternate name, TransTech Pharma Inc.). He serves as Senior Vice President for Experimental Therapeutics at Dana-Farber Cancer Institute. He serves as Director of the Center for Sarcoma and Bone Oncology in the Department of Medical Oncology at the Dana-Farber Cancer Institute and Brighasm and Women's Hospital, Boston, Massachusetts. He serves as Director of the Ludwig Center at Dana-Farber/Harvard Cancer Center and Associate Director for Clinical Sciences at the Dana-Farber/Harvard Cancer Center. He serves as Professor of Medicine at Harvard Medical School. At Dana-Farber and Harvard, Dr. Demetri leads a large multidisciplinary center focused on the specialty cancer care and science of sarcomas with a team that has consistently been at the cutting edge of developing personalized cancer therapeutics for sarcomas as a model for all cancers. He served as an Associate Professor of Medicine at Harvard Medical School. Dr. Demetri served as Scientific Advisor of Champions Oncology, Inc. He was a pioneer in the development of the Gleevec as one of the first examples of targeted cancer therapies focused on a molecularly-defined subset of sarcoma: gastrointestinal stromal tumor (GIST). Subsequently, his work has led to the FDA and worldwide regulatory approval of several other “smart drugs” for cancer, including Sutent and Stivarga for GIST, as well as Votrient and Yondelis for other sarcomas He served as Clinical Advisor of Blueprint Medicines Corporation since May 2012. He served as an Executive Director of Clinical and Translational Research at Ludwig Institute for Cancer Research Ltd. He served as a Consultant of Point Therapeutics Inc. He serves as the Chair of the Medical Advisory Board of the Sarcoma Alliance. He serves as Founding Chairman of the Clinical Advisory Board at Kolltan Pharmaceuticals, Inc. Dr. Demetri serves as Member of the Medical Advisory Board at EmergingMed, Inc. (alternate name, EmergingMed.com, Inc.). He has been a Member of Scientific Advisory Board at Plexxikon Inc. since November 6, 2006. He has been Director of Blueprint Medicines Corporation since December 2014 and has been its Member of Scientific Advisory Board since May 2012. He serves as Member of Scientific Advisory Board at Mirati Therapeutics, Inc. He serves as a Member of Scientific/Medical Advisory Board at Sarcoma Foundation of America and ZIOPHARM Oncology, Inc. He serves as a Member of Scientific Advisory Board at Kolltan Pharmaceuticals, Inc. and Caris Life Sciences, Inc. He serves as Member of the Board of Directors of the Connective Tissue Oncology Society. He served as a Director of MedPanel, LLC (alternate name, Panel Intelligence, LLC). Dr. Demetri serves as a Member of Science & Medical Advisor of N-of-One, Inc. He served as a Member of Scientific Advisory Board at Deciphera Pharmaceuticals, LLC. He served as a Member of Oncology Clinical Advisory Board at Idera Pharmaceuticals, Inc., since July 2006. He served as a Member of Clinical Advisory Board at Point Therapeutics Inc. since June 2004. He is a Member of Scientific Committee at Invivis Pharmaceuticals Inc. He is a Member of many professional societies and editorial boards of scientific journals. Dr. Demetri received the Focused Giving Program Award, Johnson and Johnson Foundation in 1993, the Emil J. Freireich Award in Clinical Cancer Research in 2002 and the Claire W. and Richard P. Morse Research Award in 2005. He is a Fellow of the American College of Physicians. He received the 2002 Emil J Freirich Award in Clinical Cancer Research from the MD Anderson Cancer Center. He completed a fellowship in Medical Oncology at the Dana-Farber Cancer Institute and Harvard Medical School, where he has served as an Attending Physician since 1989. Dr. Demetri received his undergraduate degree in Biochemistry from Harvard College and Medical Degree from Stanford University School of Medicine in 1983, Internal Medicine residency and chief residency at the University of Washington Hospitals in Seattle. 

 Pharmaceutical Sciences